Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.
Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.